Published in J Immunol Methods on October 12, 1984
Evidence that pp42, a major tyrosine kinase target protein, is a mitogen-activated serine/threonine protein kinase. Proc Natl Acad Sci U S A (1989) 3.98
A pathway for disulfide bond formation in vivo. Proc Natl Acad Sci U S A (1993) 3.86
Localization of mouse hepatitis virus nonstructural proteins and RNA synthesis indicates a role for late endosomes in viral replication. J Virol (1999) 2.49
Rapid dot-immunobinding assay on nitrocellulose for viral antibodies. J Clin Microbiol (1986) 1.89
Protection against infection with Neisseria meningitidis group B serotype 2b by passive immunization with serotype-specific monoclonal antibody. Infect Immun (1985) 1.60
Survival of athymic (nu/nu) mice after Theiler's murine encephalomyelitis virus infection by passive administration of neutralizing monoclonal antibody. J Virol (1989) 1.35
Amino acid sequence of a conserved neutralizing epitope of murine coronaviruses. J Virol (1989) 1.15
Possible role of Escherichia coli penicillin-binding protein 6 in stabilization of stationary-phase peptidoglycan. J Bacteriol (1992) 1.04
Catabolism of homologous murine monoclonal hybridoma IgG antibodies in mice. Immunology (1987) 0.94
Silencing VP28 gene of white spot syndrome virus of shrimp by bacterially expressed dsRNA. Mar Biotechnol (NY) (2007) 0.88
Oral vaccination of baculovirus-expressed VP28 displays enhanced protection against White Spot Syndrome Virus in Penaeus monodon. PLoS One (2011) 0.83
Examination of potato virus X proteins synthesized in infected tobacco plants. J Virol (1992) 0.79
Domain organization of penicillin-binding protein 5 from Escherichia coli analysed by C-terminal truncation. Biochem J (1993) 0.77
Molecular cloning and expression analysis of fushi tarazu factor 1 in the brain of air-breathing catfish, Clarias gariepinus. PLoS One (2011) 0.75
The virology and immunobiology of lymphocytic choriomeningitis virus infection. Adv Immunol (1980) 6.24
Monoclonal antibodies to lymphocytic choriomeningitis and pichinde viruses: generation, characterization, and cross-reactivity with other arenaviruses. Virology (1981) 3.26
Monoclonal antibodies to murine hepatitis virus-4 (strain JHM) define the viral glycoprotein responsible for attachment and cell--cell fusion. Virology (1982) 2.94
Coronavirus spike proteins in viral entry and pathogenesis. Virology (2001) 2.85
Murine hepatitis virus-4 (strain JHM)-induced neurologic disease is modulated in vivo by monoclonal antibody. Virology (1984) 2.57
Molecular characterization of the genomic S RNA segment from lymphocytic choriomeningitis virus. Virology (1987) 2.53
Site-specific alteration of murine hepatitis virus type 4 peplomer glycoprotein E2 results in reduced neurovirulence. J Virol (1986) 2.35
Alteration of the pH dependence of coronavirus-induced cell fusion: effect of mutations in the spike glycoprotein. J Virol (1991) 2.16
Prion protein biosynthesis in scrapie-infected and uninfected neuroblastoma cells. J Virol (1989) 2.08
A central role for CD4(+) T cells and RANTES in virus-induced central nervous system inflammation and demyelination. J Virol (2000) 2.04
Protein structure of lymphocytic choriomeningitis virus: evidence for a cell-associated precursor of the virion glycopeptides. Virology (1979) 2.00
Molecular mimicry: frequency of reactivity of monoclonal antiviral antibodies with normal tissues. J Virol (1986) 1.95
Murine coronavirus infection: a paradigm for virus-induced demyelinating disease. Trends Microbiol (1997) 1.93
The T cell chemoattractant IFN-inducible protein 10 is essential in host defense against viral-induced neurologic disease. J Immunol (2000) 1.91
Site-specific antibodies define a cleavage site conserved among arenavirus GP-C glycoproteins. J Virol (1987) 1.87
Dynamic regulation of alpha- and beta-chemokine expression in the central nervous system during mouse hepatitis virus-induced demyelinating disease. J Immunol (1998) 1.83
The viral transmembrane superfamily: possible divergence of Arenavirus and Filovirus glycoproteins from a common RNA virus ancestor. BMC Microbiol (2001) 1.80
Sequence analysis reveals extensive polymorphism and evidence of deletions within the E2 glycoprotein gene of several strains of murine hepatitis virus. Virology (1989) 1.79
The S RNA segment of lymphocytic choriomeningitis virus codes for the nucleoprotein and glycoproteins 1 and 2. J Virol (1985) 1.74
Restricted expression of viral glycoprotein in cells of persistently infected mice. Nature (1982) 1.73
Proteins of lymphocytic choriomeningitis virus: antigenic topography of the viral glycoproteins. Virology (1986) 1.71
Fine mapping of a peptide sequence containing an antigenic site conserved among arenaviruses. Virology (1988) 1.70
Acidic pH triggers LCMV membrane fusion activity and conformational change in the glycoprotein spike. Virology (1994) 1.70
Topographical mapping of epitopes on the glycoproteins of murine hepatitis virus-4 (strain JHM): correlation with biological activities. Virology (1984) 1.69
Protein-protein interactions in lymphocytic choriomeningitis virus. Virology (1991) 1.68
Mechanisms of antibody-mediated protection against lymphocytic choriomeningitis virus infection: mother-to-baby transfer of humoral protection. J Virol (1992) 1.66
Mouse hepatitis virus type 4 (JHM strains). induced fatal central nervous system disease. I. genetic control and murine neuron as the susceptible site of disease. J Exp Med (1981) 1.60
Genetic mapping of lymphocytic choriomeningitis virus pathogenicity: virulence in guinea pigs is associated with the L RNA segment. J Virol (1985) 1.60
Post-translational processing of the glycoproteins of lymphocytic choriomeningitis virus. Virology (1990) 1.58
Interferon-gamma protects against herpes simplex virus type 1-mediated neuronal death. Virology (1997) 1.57
Neutralization-resistant variants of a neurotropic coronavirus are generated by deletions within the amino-terminal half of the spike glycoprotein. J Virol (1990) 1.55
Cutaneous ulcerations and pustular psoriasis flare caused by recombinant interferon beta injections in patients with multiple sclerosis. J Am Acad Dermatol (1996) 1.55
Antibodies to GM1 and GD1b in patients with motor neuron disease without plasma cell dyscrasia. Ann Neurol (1989) 1.55
A multicenter, randomized, double-blind, placebo-controlled trial of influenza immunization in multiple sclerosis. Neurology (1997) 1.54
Survival of human carrier erythrocytes in vivo. Clin Sci (Lond) (1999) 1.53
Virus and immune responses: lymphocytic choriomeningitis virus as a prototype model of viral pathogenesis. Br Med Bull (1985) 1.52
Encephalitogenic T cell clones specific for myelin basic protein. An unusual bias in antigen recognition. J Exp Med (1985) 1.46
Virus persistence and recurring demyelination produced by a temperature-sensitive mutant of MHV-4. Nature (1982) 1.46
Coronavirus-related nosocomial viral respiratory infections in a neonatal and paediatric intensive care unit: a prospective study. J Hosp Infect (2002) 1.43
Analysis of the genomic L RNA segment from lymphocytic choriomeningitis virus. Virology (1987) 1.43
Protein structure of lymphocytic choriomeningitis virus: identification of the virus structural and cell associated polypeptides. Virology (1978) 1.43
Neutralizing epitopes of lymphocytic choriomeningitis virus are conformational and require both glycosylation and disulfide bonds for expression. Virology (1989) 1.41
The reticuloendothelium as the target in a virus infection. Pichinde virus pathogenesis in two strains of hamsters. Lab Invest (1977) 1.41
Antiviral antibodies attenuate T-cell-mediated immunopathology following acute lymphocytic choriomeningitis virus infection. J Virol (1991) 1.40
Selective localization of wild type and mutant mouse hepatitis virus (JHM strain) antigens in CNS tissue by fluorescence, light and electron microscopy. J Neuroimmunol (1981) 1.39
The V5A13.1 envelope glycoprotein deletion mutant of mouse hepatitis virus type-4 is neuroattenuated by its reduced rate of spread in the central nervous system. Virology (1992) 1.39
Ultrastructural localization of viral antigens in the CNS of mice persistently infected with lymphocytic choriomeningitis virus (LCMV). Am J Pathol (1983) 1.37
Kinetics and pH dependence of acid-induced structural changes in the lymphocytic choriomeningitis virus glycoprotein complex. Virology (1995) 1.37
Systemic alpha-interferon therapy of multiple sclerosis. Neurology (1984) 1.35
Neuroinvasion by human respiratory coronaviruses. J Virol (2000) 1.33
Human coronavirus gene expression in the brains of multiple sclerosis patients. Virology (1992) 1.32
Cell receptor-independent infection by a neurotropic murine coronavirus. Virology (1992) 1.31
Variation between strains of hamsters in the lethality of Pichinde virus infections. Infect Immun (1977) 1.28
Cytokine induction during T-cell-mediated clearance of mouse hepatitis virus from neurons in vivo. J Virol (1994) 1.25
Virus-induced immune complex disease: identification of specific viral antigens and antibodies deposited in complexes during chronic lymphocytic choriomeningitis virus infection. J Immunol (1978) 1.24
A neurologic rating scale (NRS) for use in multiple sclerosis. Neurology (1984) 1.24
Entry of mouse hepatitis virus into cells by endosomal and nonendosomal pathways. Virology (1997) 1.24
Immuno-gold localization of prion filaments in scrapie-infected hamster brains. Lab Invest (1987) 1.22
Disassociation between the in vitro and in vivo effects of nitric oxide on a neurotropic murine coronavirus. J Virol (1997) 1.22
Perturbation of differentiated functions during viral infection in vivo. I. Relationship of lymphocytic choriomeningitis virus and host strains to growth hormone deficiency. Virology (1985) 1.21
Recommendations of the Coronavirus Study Group for the nomenclature of the structural proteins, mRNAs, and genes of coronaviruses. Virology (1990) 1.21
Physicochemical properties of Marburg virus: evidence for three distinct virus strains and their relationship to Ebola virus. J Gen Virol (1988) 1.19
Disease activity markers in multiple sclerosis. Another look at suppressor cells defined by monoclonal antibodies OKT4, OKT5, and OKT8. J Neuroimmunol (1984) 1.18
Monoclonal anti-gamma interferon antibodies enhance experimental allergic encephalomyelitis. Autoimmunity (1993) 1.18
Serial passage of microglial SIV results in selection of homogeneous env quasispecies in the brain. Virology (1995) 1.18
Cell-penetrating peptide-morpholino conjugates alter pre-mRNA splicing of DMD (Duchenne muscular dystrophy) and inhibit murine coronavirus replication in vivo. Biochem Soc Trans (2007) 1.17
Protein analysis of defective interfering lymphocytic choriomeningitis virus and persistently infected cells. Virology (1979) 1.15
In vitro generation of human cytotoxic lymphocytes by virus. Viral glycoproteins induce nonspecific cell-mediated cytotoxicity without release of interferon. J Exp Med (1981) 1.13
Ibuprofen treatment versus gradual introduction of interferon beta-1b in patients with MS. Neurology (1999) 1.12
Host genetic control of mouse hepatitis virus type 4 (JHM strain) replication. I. Restriction of virus amplification and spread in macrophages from resistant mice. J Gen Virol (1984) 1.12
Protective immunity against murine hepatitis virus (MHV) induced by intranasal or subcutaneous administration of hybrids of tobacco mosaic virus that carries an MHV epitope. Proc Natl Acad Sci U S A (1999) 1.11
Protection from lethal coronavirus infection by immunoglobulin fragments. J Immunol (1995) 1.10
Multiple sclerosis in the spinal cord: MR appearance and correlation with clinical parameters. Radiology (1995) 1.10
Survival of human coronaviruses 229E and OC43 in suspension and after drying onsurfaces: a possible source ofhospital-acquired infections. J Hosp Infect (2000) 1.09
Human papillomavirus type 16 E7 peptide-directed CD8+ T cells from patients with cervical cancer are cross-reactive with the coronavirus NS2 protein. J Virol (2003) 1.09
Monoclonal antibodies to lymphocytic choriomeningitis virus react with pathogenic arenaviruses. Nature (1980) 1.06
Protection from mouse hepatitis virus type 3-induced acute disease by an anti-nucleoprotein monoclonal antibody. Brief report. Arch Virol (1987) 1.06
Sequence analysis of the membrane protein gene of human coronavirus OC43 and evidence for O-glycosylation. J Gen Virol (1992) 1.06
In vitro expression in eukaryotic cells of a prion protein gene cloned from scrapie-infected mouse brain. Proc Natl Acad Sci U S A (1988) 1.04
Comprehensive detection and identification of human coronaviruses, including the SARS-associated coronavirus, with a single RT-PCR assay. J Virol Methods (2004) 1.04
Antigenic variation among murine coronaviruses: evidence for polymorphism on the peplomer glycoprotein, E2. Virus Res (1985) 1.04
In vivo expression of major histocompatibility complex molecules on oligodendrocytes and neurons during viral infection. Am J Pathol (2001) 1.04
Acute and persistent infection of human neural cell lines by human coronavirus OC43. J Virol (1999) 1.02
Selected mutants of mouse hepatitis virus type 4 (JHM strain) induce different CNS diseases. Pathobiology of disease induced by wild type and mutants ts8 and ts15 in BALB/c and SJL/J mice. Am J Pathol (1982) 1.02
Host genetic regulation of acute MHV-4 viral encephalomyelitis and acute experimental autoimmune encephalomyelitis in (BALB/cKe x SJL/J) recombinant-inbred mice. J Neuroimmunol (1985) 1.02
Antibody prevents the establishment of persistent arenavirus infection in synergy with endogenous T cells. J Virol (1997) 1.02
Viral induction of central nervous system innate immune responses. J Virol (2005) 1.02
Protection from lethal coronavirus infection by affinity-purified spike glycoprotein of murine hepatitis virus, strain A59. Virology (1990) 1.00